SCHEMBL18483370

SCHEMBL18483370

CCc1nc(-c2cccn2C)nc(-c2cccn2C)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 4/20 0.40
GAA P10253 1/20 0.40
HSD17B10 Q99714 2/20 0.40
MAPK1 P28482 2/20 0.40
CYP2A6 P11509 1/20 0.40
CYP2A13 Q16696 1/20 0.40
NPC1 O15118 2/20 0.39
RECQL P46063 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PCSK9 Q8NBP7 1/20 0.37
ALOX15 P16050 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
SLC6A3 Q01959 1/20 0.33
NAMPT P43490 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18482878 0.79 ALDH1A1 (0.47) ALDH1A1KDM4EGAAHSD17B10MAPK1
SCHEMBL18471452 0.74 ALDH1A1 (0.40) ALDH1A1KDM4EGAAHSD17B10MAPK1
SCHEMBL1232645 0.73 KDM4E (0.45) ALDH1A1KDM4EGAAHSD17B10MAPK1
SCHEMBL3469899 0.73 KDM4E (0.42) ALDH1A1KDM4EGAAHSD17B10MAPK1
SCHEMBL2117930 0.72 ALDH1A1 (0.41) ALDH1A1KDM4EGAAHSD17B10MAPK1
SCHEMBL2115936 0.72 ALDH1A1 (0.41) ALDH1A1KDM4EGAAHSD17B10MAPK1
SCHEMBL30702649 0.71 ALDH1A1 (0.47) ALDH1A1KDM4EGAAHSD17B10MAPK1
SCHEMBL197196 0.70 PCSK9 (0.60) ALDH1A1KDM4EGAAHSD17B10CYP2A6
SCHEMBL12133854 0.69 ALDH1A1 (0.40) ALDH1A1KDM4EGAAHSD17B10MAPK1
SCHEMBL4023346 0.68 ESR1 (0.41) ALDH1A1KDM4EGAAHSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10186667-B2 Diphenylimidazole-fused, spirally configured cis-stilbene/fluorene hybrid compounds and organic light emitting device comprising the same NICHEM FINE TECHNOLOGY CO., LTD. (TW) 2019-01-22 US disclosed
US-20170040548-A1 DIPHENYLIMIDAZOLE-FUSED, SPIRALLY CONFIGURED CIS-STILBENE/FLUORENE HYBRID COMPOUNDS AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME NICHEM FINE TECHNOLOGY CO., LTD. (TW) 2017-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10186667-B2 Diphenylimidazole-fused, spirally configured cis-stilbene/fluorene hybrid compounds and organic light emitting device comprising the same SLCO4C1, SLCO2B1, SLCO1B1 ALDH1A1 1491/4885KDM4E 4755/4885GAA 2743/4885
US-20170040548-A1 DIPHENYLIMIDAZOLE-FUSED, SPIRALLY CONFIGURED CIS-STILBENE/FLUORENE HYBRID COMPOUNDS AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME SLCO4C1, SLCO2B1, SLCO1B1 ALDH1A1 1491/4885KDM4E 4755/4885GAA 2743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.